• Rizonib 250 mg (Crizotinib): ALK Positive Lung Cancer Quick View
    • Rizonib 250 mg (Crizotinib): ALK Positive Lung Cancer Quick View

    • Rizonib 250 mg (Crizotinib): ALK Positive Lung Cancer

    • Rizonib 250 mg (Crizotinib) is an advanced oral medication used to treat non-small cell lung cancer (NSCLC) that is ALK-positive (anaplastic lymphoma kinase-positive) or ROS1-positive. Crizotinib, the active ingredient in Rizonib, is a targeted therapy that works by inhibiting the abnormal proteins responsible for driving the growth of cancer cells. This powerful treatment offers hope for patients with advanced or…
    • Read more